Form 10-K INOVIO PHARMACEUTICALS, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Inovio Pharma (INO) Posts Q4 Loss of 25c/Share
March 14, 2016 6:13 AM EDTInovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.25), which may not compare with the analyst estimate of ($0.20). Revenue for the quarter came in at $5.94 million versus the consensus estimate of $6.96 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... More